Trial Profile

Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals with Opioid Use Disorder

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Psilocybin (Primary)
Indications Opioid-related disorders
Focus Pharmacodynamics

Most Recent Events

09 Apr 2025 According to Filament Health media release, The US FDA has authorized this study at the University of Pennsylvania. And, The trial is expected to begin dosing in by Q3 2025.
30 Mar 2025 Planned initiation date changed from 1 Mar 2025 to 1 Apr 2025.
11 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com